NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

LC,

Thanks for asking. The focus is often on DCVax-L or the emerging combo data…

LC, we can always count on you to broaden the conversation. 😉 … It is a good idea to highlight Direct too…

DCVax-Direct is an entirely separate topic and presents additional potential value beyond resectable cancer.

For some preliminary background about Direct, let’s search the web with an AI app:

“DCVax-Direct is a form of cancer immunotherapy being developed by Northwest Biotherapeutics. It is designed to target a broad range of inoperable solid tumors. Here are the key aspects of DCVax-Direct:

1. **Mechanism of Action:** DCVax-Direct involves the same mechanism as DCVax-L, but with a crucial difference. In DCVax-Direct, dendritic cells are directly injected into the tumor, where they take up tumor target proteins in situ. This is in contrast to DCVax-L, where tumor lysate from surgically resected tumor tissue is used.

2. **Phase 1 Trial Results:** The Phase 1 trial of DCVax-Direct showed positive results in treating more than a dozen different types of inoperable solid tumors. This indicates the potential effectiveness of DCVax-Direct across a diverse range of tumor types.

3. **Future Development:** Northwest Biotherapeutics plans to continue the clinical development of DCVax-Direct for a wide range of inoperable solid tumors, building on the success of their Phase 1 trials.

In summary, DCVax-Direct represents an innovative approach in cancer immunotherapy, especially for inoperable solid tumors, leveraging the body's immune system to target and destroy cancer cells.”
—ChatGPT